---
title: "Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Real-world evidence questions"
description: "Real-world evidence questions on Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What were TRODELVY real-world survival outcomes in previously treated metastatic TNBC? What TRODELVY side effects and dose changes were seen in real-world use? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/real-world-evidence"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Real-world evidence questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Trodelvy](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)

## Real-world evidence

<a id="trodelvy-real-world-results"></a>

### What were TRODELVY real-world survival outcomes in previously treated metastatic TNBC?

> “A retrospective, observational cohort study assessed real-world clinical outcomes in patients with mTNBC treated with TRODELVY as 2L and later.<sup>5</sup>
>
> Limitations: These EHR-derived, retrospective data were not powered for statistical analysis and should be considered descriptive only. The results require cautious interpretation and could represent chance findings. Data entry errors could have occurred. It is likely there are missing data.<sup>5</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=A%20retrospective%2C%20observational%20cohort%20study,is%20likely%20there%20are%20missing)

> “For the total population (N=230), the mPFS was 3.8 months (95% CI: 3.1–4.3) and the mOS was 10 months (95% CI: 8.3–11.1)<sup>5</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=For%20the%20total%20population%20%28N%3D230%29%2C,was%2010%20months%20%2895%25%20CI%3A)

> “Real-world OS rate (95% CI)
> 2L mTNBC (n=77)
> 3L+ mTNBC (n=153)
> Total (N=230)
> 12-month
> 51% (37–64)
> 35% (26–44)
> 40% (33–48)
> 24-month
> 32% (13–54)
> 20% (11–29)
> 23% (15–32)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=Real%2Dworld%20OS%20rate%20%2895%25%20CI%29,23%25%20%2815%E2%80%9332%29)

> “From April 2020 to May 2022, 230 adult female patients with mTNBC were treated with TRODELVY in the 2L or later setting. 33% and 67% of patients received TRODELVY in the 2L and 3L+ settings, respectively.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=From%20April%202020%20to%20May,2L%20and%203L%2B%20settings%2C%20respectively.)

<a id="trodelvy-real-world-tolerability"></a>

### What TRODELVY side effects and dose changes were seen in real-world use?

> “A retrospective, observational cohort study assessed real-world clinical outcomes in patients with mTNBC treated with TRODELVY as 2L and later.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=A%20retrospective%2C%20observational%20cohort%20study,TRODELVY%20as%202L%20and%20later.)

> “Real-world safety data (n=230)<sup>5</sup>
>
> Limitations: Underreporting of AEs and dose modifications in physicians’ notes may have occurred with an unknown impact on the results.<sup>5</sup>
>
> Dose reduction and interruptions were observed in 34% and 58% of all patients, with 26% and 39% due to toxicity, respectively; 7% discontinued TRODELVY due to toxicity<sup>5</sup>
> Fatigue was reported in 45%, neutropenia in 33%, and diarrhea in 30% of patients<sup>5</sup>
> Concomitant administration of G-CSF was observed in 58% of all patients, with most of these patients (99/134=74%) having received G-CSF with prior anticancer treatment<sup>5</sup>
> 15% of patients received G-CSF for the first time during treatment with TRODELVY. Among these patients, the median time from TRODELVY start to G-CSF use was 8.5 days (IQR: 8.0–29.0)”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=Real%2Dworld%20safety%20data,was%208.5%20days%20%28IQR%3A%208.0%E2%80%9329.0%29)

## Related pages
- [Medical information: Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/guidelines)
